BIOQ (Bioqual) Moat Score: 4/10 (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOQ Bioqual Inc BIOQ
54 GF Score
Price $33.00
! 4 Warning Signs
View Full Analysis

What is Bioqual Moat Score?

Bioqual BIOQ 54 Moat Score is 4 as of Aug. 28, 2026. GuruFocus rates BIOQ with a GF Score™ of 54/100. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Bioqual ranks better than 82.63% on this metric.

Bioqual has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Bioqual has Narrow Moat: Bioqual Inc has a discernible but modest moat due to its specialized services in the biotech sector. It benefits from some customer loyalty and intellectual property, but lacks strong market leadership and significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bioqual might have Narrow Moat - Discernible but modest moat.

Bioqual  (OTCPK:BIOQ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bioqual Moat Score Related Terms

BIOQ vs ADVB, QUCY, MDXH: Moat Score Comparison

For the Diagnostics & Research subindustry, Bioqual's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioqual Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioqual's Moat Score distribution charts can be found below:

* The bar in red indicates where Bioqual's Moat Score falls into.


BIOQ
54GF Score
Bioqual Inc BIOQ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Bioqual (BIOQ) has a Moat Score of 4 as of Aug. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bioqual ranks #37 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 17.4%.
Is Bioqual's Moat Score too high?
Bioqual's current Moat Score is 4. Based on the distribution chart, Bioqual ranks #37 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bioqual has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Bioqual's Moat Score compare to ADVB and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Bioqual ranks #37 out of 213 companies for Moat Score. This places Bioqual in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Bioqual's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioqual stock overvalued right now?
Bioqual (BIOQ) has a current Moat Score of 4. The current Moat Score is 4. Bioqual's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bioqual (BIOQ), the current Moat Score is 4 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioqual Business Description

Address 9620 Medical Center Drive, Suite 310, Rockville, MD, USA, 20850
Bioqual Inc is a United States-based medical research company. It is engaged in providing contract research services focused on animal models of human diseases, including AIDS, influenza, RSV infection, flavivirus infections like Zika and Dengue, malaria, hepatitis, and cancer. The company is also involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. It provides services to the federal government, universities, and the life science and pharmaceutical industries. It derives revenue from the provision of contract research services.
54GF Score

Get the complete analysis for BIOQ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.00
Price